- Trials with a EudraCT protocol (356)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
356 result(s) found for: Blood culture.
Displaying page 1 of 18.
EudraCT Number: 2008-005278-11 | Sponsor Protocol Number: A8851022 | Start Date*: 2009-03-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005277-35 | Sponsor Protocol Number: A8851021 | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000780-24 | Sponsor Protocol Number: 9463-CL-2303 | Start Date*: 2012-07-24 |
Sponsor Name:Astellas Pharma Global Development, Inc. | ||
Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | ||
Medical condition: Neonatal Candidiasis | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GR (Completed) HU (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004854-97 | Sponsor Protocol Number: A8851019 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE... | |||||||||||||
Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004440-19 | Sponsor Protocol Number: CLAM320B2202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regi... | |||||||||||||
Medical condition: Treatment of multidrug-resistant pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000755-13 | Sponsor Protocol Number: DACLEAN | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:CHU de Poitiers | |||||||||||||
Full Title: ESTIMATION OF THE INCIDENCE OF COLONIZATION OF PERIPHERAL VENOUS CATHETERS AFTER SKIN DISINFECTION WITH 0.5% SODIUM HYPOCHLORITE, PRECEDED OR NOT BY AN APPLICATION OF 70% ETHANOL: PILOT, MONOCENTRI... | |||||||||||||
Medical condition: Bacterial colonization of peripheral venous catheters | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004150-32 | Sponsor Protocol Number: A8851008 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Pfizer, Spain | |||||||||||||
Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM... | |||||||||||||
Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004804-38 | Sponsor Protocol Number: 073-202 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:ViroDefense Inc | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V... | |||||||||||||
Medical condition: Poliomyelitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000244-26 | Sponsor Protocol Number: PC-ASP-004 | Start Date*: 2018-08-21 | ||||||||||||||||
Sponsor Name:Pulmocide Ltd | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast... | ||||||||||||||||||
Medical condition: Pulmonary aspergillosis and candidiasis of lung | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012848-16 | Sponsor Protocol Number: A1501085 | Start Date*: 2010-04-28 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA | |||||||||||||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH... | |||||||||||||||||||||||
Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001534-13 | Sponsor Protocol Number: V58P12 | Start Date*: 2007-11-08 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cel... | ||
Medical condition: Healthy pediatric population from 3-17 years | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) LT (Completed) FI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002962-19 | Sponsor Protocol Number: SKA 001 | Start Date*: 2011-10-04 |
Sponsor Name:University College Dublin | ||
Full Title: CHLORHEXIDINE VERSUS POVIDONE-IODINE FOR SKIN ANITSEPSIS PRIOR TO CENTRAL VENOUS CATHETER INSERTION IN PRETERM INFANTS: PROTOCOL FOR A RANDOMISED TRIAL (THE SKA TRIAL) | ||
Medical condition: Blood stream infections in neonates | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005229-31 | Sponsor Protocol Number: 242-07-204 | Start Date*: 2008-02-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: A Multi center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC-67683 in Patients with Pulmonary Sputum Cu... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019984-12 | Sponsor Protocol Number: AMNCH-TCD-CHG-1-2010 | Start Date*: 2010-07-21 |
Sponsor Name:Adelaide & Meath Hospital, incorporating The National Children's Hospital | ||
Full Title: A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine... | ||
Medical condition: Prevention of central venous catheter-related infections in haemodialysis patients. This trial will evaluate the effectiveness of 2% chlorhexidine gluconate in 70%isopropyl alcohol as a skin, exit... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003571-56 | Sponsor Protocol Number: APX001-201 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Amplyx Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ... | |||||||||||||
Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005738-13 | Sponsor Protocol Number: TPLBIS20 | Start Date*: 2021-02-16 |
Sponsor Name:Region Skåne | ||
Full Title: Pivmecillinam with Amoxicillin/clavulanic acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales. | ||
Medical condition: Urinary tract infection and/or bacteremia caused by extended spectrum beta-lactamases-producing Enterobacterales | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000910-12 | Sponsor Protocol Number: HT011 | Start Date*: 2020-07-01 | |||||||||||
Sponsor Name:Helperby Therapeutics Ireland Limited | |||||||||||||
Full Title: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colis... | |||||||||||||
Medical condition: complicated urinary tract infection (cUTI). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001576-15 | Sponsor Protocol Number: MK-3009-029 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years with Complicated Sk... | |||||||||||||
Medical condition: Complicated Skin and Soft Tissue Infections or Bacteremia caused by Gram-positive cocci | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
